Back
Compare AU
Compare DRUG vs. IZZ
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the iShares China Large-Cap ETF (IZZ). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | IZZ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 66 |
Median incremental investment | $745.07 | $1,993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,592.71 | $3,719.98 |
Average age group | > 35 | > 35 |
Key Summary
DRUG | IZZ | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | IZZ.AX was created on 2004-10-05 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 429.35m in AUM and 52 holdings. The fund aims to provide investors with the performance of the FTSE China 50 Index, before fees and expenses. The index is designed to measure the performance of 50 of the largest and most liquid Chinese companies which trade on the Hong Kong Stock Exchange |
Top 3 holdings | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) | TENCENT HOLDINGS LTD (10.00 %) ALIBABA GROUP HOLDING LTD (8.96 %) XIAOMI CORP (7.49 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Other (59.03 %) Consumer Discretionary (16.54 %) Communication Services (12.68 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | China (91.42 %) Hong Kong (6.92 %) United States (1.66 %) |
Management fee | 0.57 % | 0.74 % |
Key Summary
DRUG | IZZ | |
|---|---|---|
Issuer | BetaShares | iShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | FTSE China 50 Net Tax USD Index |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.74 % |
Price | $8.54 | $51.31 |
Size | $176.672 million | $416.854 million |
10Y return | N/A | 17.90 % |
Annual distribution yield (5Y) | 1.92 % | 2.26 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 15/11/2007 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | IZZ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 66 |
Median incremental investment | $745.07 | $1,993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,592.71 | $3,719.98 |
Average age group | > 35 | > 35 |
Pros and Cons
DRUG | IZZ | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | IZZ |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |